NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

Phase 3

Completed

Conditions: Stage III Breast Cancer AJCC v6
Recurrent Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7
Invasive Breast Carcinoma

Interventions: Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Drug: Letrozole
Other: Questionnaire Administration
Drug: Tamoxifen Citrate

First Posted Date: 2008-01-28

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 394

Registration Number: NCT00601900

Locations: 🇺🇸
Providence Hospital, Mobile, Alabama, United States
🇺🇸
Sparks Regional Medical Center, Fort Smith, Arkansas, United States
🇺🇸
East Bay Medical Oncology Hematology Medical Associates-Antioch, Antioch, California, United States

and more 517 locations

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Stage II Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Biological: Rituximab
Drug: Lenalidomide

First Posted Date: 2008-01-28

Last Posted Date: 2023-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 418

Registration Number: NCT00602459

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
PCR Oncology, Arroyo Grande, California, United States
🇺🇸
Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States

and more 361 locations

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Lenalidomide
Drug: Prednisone
Other: Quality-of-Life Assessment
Drug: Thalidomide

First Posted Date: 2008-01-28

Last Posted Date: 2025-04-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 306

Registration Number: NCT00602641

Locations: 🇺🇸
Providence Hospital, Mobile, Alabama, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Sparks Regional Medical Center, Fort Smith, Arkansas, United States

and more 387 locations

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

Phase 2

Completed

Conditions: Estrogen Receptor-positive Breast Cancer
Progesterone Receptor-negative Breast Cancer
Progesterone Receptor-positive Breast Cancer
Stage IV Breast Cancer
Recurrent Breast Cancer

Interventions: Radiation: F-18 16 alpha-fluoroestradiol
Radiation: fludeoxyglucose F 18
Procedure: positron emission tomography
Procedure: computed tomography
Other: laboratory biomarker analysis

First Posted Date: 2008-01-28

Last Posted Date: 2020-02-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00602043

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy

Phase 1

Completed

Conditions: Recurrent Fallopian Tube Carcinoma
Recurrent Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Wild-type Reovirus

First Posted Date: 2008-01-28

Last Posted Date: 2016-08-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT00602277

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Secondary Acute Myeloid Leukemia
Adult Acute Myelomonocytic Leukemia (M4)
Untreated Adult Acute Myeloid Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monocytic Leukemia (M5b)

Interventions: Drug: tipifarnib
Drug: etoposide

First Posted Date: 2008-01-28

Last Posted Date: 2014-10-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 84

Registration Number: NCT00602771

Locations: 🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

and more 2 locations

Intraperative Assessment of Renal Perfusion Using Infrared Imaging

Completed

Conditions: Kidney Transplantation

First Posted Date: 2008-01-16

Last Posted Date: 2012-04-06

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registration Number: NCT00595179

Locations: 🇺🇸
National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK), 9000, Bethesda, Maryland, United States

Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

Phase 3

Completed

Conditions: Breast Cancer
Cyclophosphamide
High Risk
Doxorubicin
Positive Nodes

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: G-CSF
Drug: tamoxifen
Drug: ciprofloxacin

First Posted Date: 2008-01-11

Last Posted Date: 2017-08-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00590785

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Promyelocytic Leukemia (M3)
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia

Interventions: Drug: selumetinib

First Posted Date: 2008-01-09

Last Posted Date: 2015-08-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT00588809

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

Phase 2

Completed

Conditions: Stage III Prostate Cancer
Prostate Adenocarcinoma
Stage I Prostate Cancer
Stage IIA Prostate Cancer
Stage IIB Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: Goserelin Acetate
Other: Laboratory Biomarker Analysis
Drug: Leuprolide Acetate
Procedure: Therapeutic Conventional Surgery
Drug: Vorinostat

First Posted Date: 2008-01-09

Last Posted Date: 2017-10-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00589472

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCSF Medical Center-Parnassus, San Francisco, California, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 12 locations

AI-Powered Research

Premium Access

NATIONAL INSTITUTES OF HEALTH

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy

Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia

Intraperative Assessment of Renal Perfusion Using Infrared Imaging

Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer